Bvf Inc Janux Therapeutics, Inc. Transaction History

Bvf Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$35.12 - $64.78 $87 Million - $161 Million	-2,478,290 Reduced 84.88%	441,528 $18.5 Million
Q1 2024 May 15, 2024	SELL	$7.93 - $49.75 $13.2 Million - $82.6 Million	-1,660,000 Reduced 36.25%	2,919,818 $110 Million
Q3 2023 Nov 14, 2023	BUY	$9.56 - $14.0 $4.52 Million - $6.62 Million	472,873 Added 11.51%	4,579,818 $46.2 Million
Q2 2023 Aug 14, 2023	BUY	$11.08 - $15.92 $27.9 Million - $40.1 Million	2,521,268 Added 159.0%	4,106,945 $48.7 Million
Q1 2023 May 15, 2023	BUY	$11.25 - $22.21 $1.3 Million - $2.56 Million	115,343 Added 7.84%	1,585,677 $19.2 Million
Q2 2022 Aug 15, 2022	BUY	$9.52 - $15.65 $3.12 Million - $5.13 Million	327,994 Added 28.71%	1,470,334 $18 Million
Q1 2022 May 16, 2022	BUY	$13.24 - $20.24 $1.66 Million - $2.53 Million	125,026 Added 12.29%	1,142,340 $16.4 Million
Q3 2021 Nov 15, 2021	SELL	$20.7 - $34.69 $3.3 Million - $5.53 Million	-159,367 Reduced 13.54%	1,017,314 $22 Million
Q2 2021 Aug 16, 2021	BUY	$18.58 - $25.37 $21.9 Million - $29.9 Million	1,176,681 New	1,176,681 $29.4 Million

166

37.6M

85.3K

654K

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $1.88B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.